GB1182320A - Dihydroorotic and Salts - Google Patents

Dihydroorotic and Salts

Info

Publication number
GB1182320A
GB1182320A GB5814067A GB5814067A GB1182320A GB 1182320 A GB1182320 A GB 1182320A GB 5814067 A GB5814067 A GB 5814067A GB 5814067 A GB5814067 A GB 5814067A GB 1182320 A GB1182320 A GB 1182320A
Authority
GB
United Kingdom
Prior art keywords
dec
improve
hydroxy
dihydroorotic
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5814067A
Inventor
Rolf Wilhelm Pfirrmann
Emil Hofstetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Priority to GB5814067A priority Critical patent/GB1182320A/en
Priority to NL6818217A priority patent/NL6818217A/xx
Priority to CH1891168A priority patent/CH510674A/en
Priority to FR179091A priority patent/FR8234M/fr
Priority to ES361702A priority patent/ES361702A1/en
Priority to BE725874D priority patent/BE725874A/xx
Priority to DE19681816097 priority patent/DE1816097A1/en
Publication of GB1182320A publication Critical patent/GB1182320A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1,182,320. Medicines comprising dihydroorotic acid salts. ED. GEISTLICH SOHNE A.G. 23 Dec., 1968 [21 Dec., 1967], No. 58140/67. Heading A5B. [Also in Division C2] Pharmaceutical compositions comprise at least one salt of dihydro-orotic acid with a primary, secondary or tertiary aliphatic amine containing at least one other hydrophilic group selected from hydroxy, esterified hydroxy, carboxy, amino or carbamoyl, in the molecule together with a pharmaceutical carrier or diluent and optionally vitamins, minerals, amino acids or enzymes. They may be administered orally, rectally, parenterally or topically and are used to improve the flow of blood through the capillaries and vascular system as well as to improve the depth of sleep, level of depression and exhaustion and alertness.
GB5814067A 1967-12-21 1967-12-21 Dihydroorotic and Salts Expired GB1182320A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB5814067A GB1182320A (en) 1967-12-21 1967-12-21 Dihydroorotic and Salts
NL6818217A NL6818217A (en) 1967-12-21 1968-12-18
CH1891168A CH510674A (en) 1967-12-21 1968-12-19 Process for the preparation of salts of dihydro-orotic acid with primary, secondary or tertiary amines
FR179091A FR8234M (en) 1967-12-21 1968-12-19
ES361702A ES361702A1 (en) 1967-12-21 1968-12-20 Dihydroorotic and Salts
BE725874D BE725874A (en) 1967-12-21 1968-12-20
DE19681816097 DE1816097A1 (en) 1967-12-21 1968-12-20 Amine salts of orotic dihydroorotic acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5814067A GB1182320A (en) 1967-12-21 1967-12-21 Dihydroorotic and Salts

Publications (1)

Publication Number Publication Date
GB1182320A true GB1182320A (en) 1970-02-25

Family

ID=10480857

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5814067A Expired GB1182320A (en) 1967-12-21 1967-12-21 Dihydroorotic and Salts

Country Status (7)

Country Link
BE (1) BE725874A (en)
CH (1) CH510674A (en)
DE (1) DE1816097A1 (en)
ES (1) ES361702A1 (en)
FR (1) FR8234M (en)
GB (1) GB1182320A (en)
NL (1) NL6818217A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396857A1 (en) * 1989-04-15 1990-11-14 Azuchemie, Dr. Med. R. Müller Gmbh External preparation and use of
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254202A1 (en) * 2003-06-13 2004-12-16 The Procter & Gamble Company Method of promoting sleep using topical administration of vasoactive agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396857A1 (en) * 1989-04-15 1990-11-14 Azuchemie, Dr. Med. R. Müller Gmbh External preparation and use of
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes

Also Published As

Publication number Publication date
NL6818217A (en) 1969-06-24
ES361702A1 (en) 1970-11-16
CH510674A (en) 1971-07-31
DE1816097A1 (en) 1969-09-25
FR8234M (en) 1970-09-28
BE725874A (en) 1969-06-20

Similar Documents

Publication Publication Date Title
GB1198764A (en) A Urate Oxidase and process for the production thereof
GB1221393A (en) Improvements in or relating to hepato-protective drugs
GB1182320A (en) Dihydroorotic and Salts
GB1225462A (en)
GB1237352A (en) Substituted propylamines
GB1252286A (en)
GB1125349A (en) Soluble salts of ellagic acid
IE35507L (en) Preparations containing tetrahydrocarbazole¹derivatives
GB1210968A (en) Improvements in or relating to the treatment of gastric ailments
GB1256723A (en)
GB1460325A (en) Pharmaceutical composition intended for relieving pain and producing analgesia
GB1197389A (en) Heterocyclic Dithiocarboxylic Acids
GB1187546A (en) Propanolamine derivatives
IE33519L (en) Benzylhydrazides
GB1169074A (en) Improvements in or relating to Hepato-Protective Drugs
GB1293691A (en) TREATMENT OF MAREK'S DISEASE WITH p-AMINO-p'-UREIDODIPHENYL SULFONE
GB1261660A (en) alpha-HYDRAZINO ACIDS
IE33520L (en) Benzylhydrazides
GB1327469A (en) Pharmaceutical compositions for inhibiting indoleamine n-methyl transferase
GB1386927A (en) Preparations for combatting swine dysentery
GB1368251A (en) Theophylinylmethylethanoic acid ester
GB1190680A (en) Halocinnamoyl Piperidines and Morpholines and Pharmaceutical Compositions Containing Them
IE34386L (en) Acetylsalicylic acid-containing composition
GB1290593A (en)
GB1392004A (en) Propoxyphene salts

Legal Events

Date Code Title Description
PS Patent sealed
PLNP Patent lapsed through nonpayment of renewal fees